EPP Dynamic Talks – Lifesciences (May 18-27, 2021)

Pinar Egeli

20 years experienced regional pricing and market access professional dedicated to support the growth markets in attaining sustainable quality healthcare access through value-based pricing and impact measurement studies. Evidence Based Value Storyteller demonstrating the public health and economical outcomes of access to medical technology could improve the health of the population in growth markets.
• Total of 25 years of marketing experience; 10+ years of Pricing & 5+ years of Market Access Health Economics and Outcomes Research.
• Evidence backed storyteller of value - Outcomes sales enabler through generating proof points to support value propositions
• Value based price setting, getting and netting to balance profitability, affordability and access.
• ICF Certified coach
• Social Value & SROI Accredited Practitioner
• Lecturer - Taught Product Management & Healthcare Management classes as part time lecturer at MBA program.

Steve Pierson

Steve started his career in Finance with Hewlett-Packard (eventually becoming part of Philips Healthcare), holding positions in cost accounting, FP&A, and a divisional controllership. In 2007 he moved into his first Pricing role supporting the North American Imaging Systems business. In this and subsequent roles within Philips he was responsible for deployment of deal approval processes and tools as well as the broad execution of pricing strategy. In 2017 Steve joined Smith & Nephew as VP of Pricing Strategy where he is applying his experience to improve pricing strategy and execution within the firm.

Alexander Natz

Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org) in Brussels and advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law perspective.
From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie e.V. (BPI). Before, he has been a lawyer at Sträter Law Firm in Germany with a special focus on managed entry agreements and licensing of pharmaceuticals. Dr. Natz has also worked in the field of competition law with the European Commission and in the pharmaceutical industry. As a research assistant at Duke University (USA) he has dealt with international pharmaceutical law. His doctorate was supervised by the former judge at the European Court of Justice, Prof. Dr. Dr. Ulrich Everling.

Jaime Osborn

Richard Charter

Ed Corbett

As the lead for EVERSANA’s EMEA management consulting practice, Ed specializes in commercial and corporate strategy and has significant national and global launch experience. He has helped a diverse set of clients from big pharma to biotech solve a wide range of challenges, including US entry strategy, EU launch excellence, due diligence, and portfolio optimization. Close to 20 years ago, he began his career in the pharmaceutical industry as a sales representative before moving into increasingly senior commercial roles at the local and global level.
Ed earned an MA in biological sciences from Brasenose College, University of Oxford. He is also a Lean Six Sigma Black Belt and is PRINCE2 project management qualified.

Elenora Mazzoni

Graduated in economics at the University of Rome - La Sapienza, after a collaboration as a research assistant with the Fondazione Brodolini, she worked for the Centro Europa Ricerche. She studied the main econometric techniques for evaluation of public intervention at the IRVAPP di Trento and at the summer school in Econometrics Cide – Bank of Italy. She is currently employed at I-Com as Innovation Area Director. She coordinates the working group that carries out economic and regulatory researches in the field of health economics and public policies impact analysis.

Elisabete Goncalves

Elisabete Gonçalves acquired her degree in Pharmacy by the School of Pharmacy of the Classical University of Lisbon. She is an experience professional in the pharmaceutical area having held positions in the Regulatory Affairs, Quality Assurance, Health Technology Assessment and Market Access areas. She has developed her career firstly in the pharmaceutical industry, and later in consulting. Presently she is Associate Director, HTA&Market Access, at CTI, Clinical Trial&Consulting.
She obtained the title of Regulatory Affairs Specialist by Portuguese Pharmaceutical Society.
She has two Post-Graduate Diplomas, one in Regulation and Assessment of Medicinal and Health Products by the School of Pharmacy of the Classical University of Lisbon (2006) and another in Economic Evaluation of Medicinal Products by IDEFE - ISEG. She attended a course in Bioethics in the Faculty of Law of the University of Lisbon.

Richard Rahul

Richard Rahul is a Senior Manager in Monitor Deloitte. His core focus is on Life Sciences (Big pharma/medium pharma) and healthcare industries, besides health technology/digital health based firms. Richard’s expertise is in go-to market model optimization, innovative pricing models, value based selling, patient/customer experience design and operations, pricing and market access. He brings a global perspective having led and successfully executed engagements in the US, cross-EU and in China/India.

Imran Ladha

Imran Ladha is a Global Strategic Pricing Associate Director in EUSA Pharma. His core focus is on Strategic Pricing and Market Access within the Pharmaceutical Industry. Imran started his career in Johnson and Johnson focusing on the health economics, market access and reimbursement of medical technologies. Following on from this he had multiple roles in market access and pricing at Janssen-Cilag UK and EMEA. Imran moved to EUSA Pharma where he managed global strategic pricing across the portfolio and the market access and reimbursement of renal cell carcinoma within Europe. Imran specialises in global pricing, market access strategy and execution with significant national and global experience.